How Quitting Smoking Can Quickly Lower Risk Of A-Fib
Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.
Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."
"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.
The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.
"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.
The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.
Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:
1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.
2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.
3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.
4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.
5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.
6. Drinking water can help flush nicotine out of your system faster, reducing cravings.
7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.
Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.
Credit: iStock
Air pollution is emerging as an important risk factor for lung cancer in India, with more young people and women who have never smoked being diagnosed with the disease, said Dr Abhishek Shankar, Associate Professor of Radiation Oncology at the All India Institute of Medical Sciences (AIIMS).
Speaking to HealthandMe, Dr Abhishek said nearly 50% of lung cancer cases are now unrelated to smoking, marking a shift from the earlier pattern, when more than 90% of cases were associated with smoking.
“So, now we see that nearly 50% lung cancer cases are not related to smoking, otherwise it was more than 90% related to smoking,” he said.
More Young People And Women Who Never Smoked Are Being Diagnosed
Lung cancer has traditionally been associated with older male smokers. However, Dr Abhishek said he is seeing more younger people and women who have never smoked being diagnosed with the disease.
He believes air pollution could be contributing to this changing pattern.
“Now the air pollution is emerging as a risk factor and when we have more number of younger people and women who never smoke, never been exposed to any kind of, you know, second or third smoke is now coming with lung cancer.”
How Is PM2.5 Linked To Lung Cancer?
“The answer is very simple that air pollution has a lot much to do in terms of lung cancer in India,” Dr Abhishek said.
According to the World Health Organization (WHO), 99% of the global population breathes air that exceeds its guideline limits and contains high levels of pollutants. Low- and middle-income countries face the highest exposures.
The International Agency for Research on Cancer (IARC) classified outdoor air pollution as a Group 1 carcinogen in 2013, identifying lung cancer as one of the cancers associated with exposure.
Delhi's air quality has deteriorated sharply in recent weeks following Diwali. PM2.5 concentrations in several parts of the capital exceeded 66 times the WHO's recommended 24-hour guideline.
Long-term exposure to fine particulate matter is also a concern for children, as it can impair lung development and affect the maximum lung capacity they attain in adulthood. PM2.5's tiny particles can penetrate deep into the lungs.
Dr Abhishek pointed to research examining the relationship between particulate matter and cancer.
“Now, there are studies about the causal relationship between air pollution and lung cancer, particularly PM 2.5.”
He added that researchers have also investigated the association between different air pollutants and cancer.
“So, there are many cancers which have been studied in reference to different components of AQI, primarily the PM 2.5, PM 10 and I think they have been associated with cancer.”
Researchers are also investigating whether specific biomarkers can help identify people more susceptible to pollution-related lung cancer.
“At the same time, we are just talking about the PM 2.5 exposure-based biomarkers; what are the, you know, unique biomarkers that are expressed only in PM 2.5 exposure-based lung cancer, and we want to identify the susceptible lung cancer population women in those cohorts.”
Dr Abhishek advised people to avoid going outdoors unless necessary during periods of severe pollution. However, he acknowledged that staying indoors is not always practical, particularly for those who need to commute to work.
He recommended wearing N95 masks to reduce exposure to fine particulate matter.
“N95 is useful. This is said to reduce exposure to the, you know, fine particles even.”
He also highlighted the use of indoor air purifiers, which can improve indoor air quality and make breathing easier. However, he noted that more research is needed to establish whether these measures reduce the risk of acute and chronic diseases.
Dr Abhishek is involved in two studies examining air pollution, lung cancer risk and screening in India.
The AIR CARE study will investigate how different components of PM2.5 contribute to lung cancer, how pollution interacts with other risk factors such as smoking, and whether exposure-based risk assessment and biomarkers can help identify high-risk groups.
The second, the Indian Lung Screening Trial, will involve around 10 centres across the country. It will assess lung cancer screening among people aged 50–80 with a smoking history of at least 20 pack-years.
The trial aims to generate evidence on lung cancer screening in the Indian population, building on findings from international studies. Dr Abhishek said initial trends from both studies are expected by the end of next year.
Credit: AI-generated image
The tiny particles of plastic found in food packaging, takeaway containers and almost everywhere in the environment may be quietly contributing to cancer risk. A new study has found that long-term exposure to microplastics could promote colorectal cancer, one of the deadliest forms of cancer.
The study published in Molecular Cancer recently found that exposure to polystyrene nanoplastics promoted tumour development in mice that were genetically at risk of colorectal cancer.
Researchers also observed growth of more tumours and more severe disease in animals exposed to microplastics than in those that were not exposed.
The findings offer a possible biological link between plastic pollution and cancer. However, the research has a limitation that it was conducted in animals, which means it did not conclusively prove that microplastics cause colon cancer.
Also read: Ivonescimab: Why Did US FDA Reject China's Promising Lung Cancer Drug?
Microplastics are plastic particles smaller than five millimetres, while nanoplastics are even tinier particles that are generally measured at the nanometre scale. They can enter the human body through food, drinking water and inhalation.
The latest research, conducted by scientists at Central South University in China, focused on polystyrene nanoplastics. Polystyrene is commonly used in disposable food containers, packaging materials and foam cups.
Researchers found that these particles accumulated predominantly in the colon of mice following long-term oral exposure. They also caused structural damage to the tiny, finger-like projections called microvilli that line the intestinal cells and help with nutrient absorption.
The exposure to microplastics not only disrupted the balance of gut bacteria but also affected the immune system's ability to fight tumour growth.
The researchers identified a mechanism that involved the gut microbiome, bacterial metabolites and immune cells. Exposure reduced levels of a beneficial bacterium called Faecalibaculum rodentium, which helped lower production of propionic acid, a short-chain fatty acid.
This reduction affected the activity of Th17 immune cells and the production of IL-17A, weakening an immune response involved in controlling tumour growth.
Also read: Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours
The researchers exposed the mice to a chemical treatment that causes colorectal cancer, which helped them investigate whether long-term exposure to nanoplastic exposure fueled tumour growth.
Animals exposed to polystyrene nanoplastics developed more tumours, with greater tumour severity, than those that were not exposed.
The findings suggest that nanoplastics may affect several processes involved in cancer development, including damage to the intestinal lining, changes in gut bacteria and changes in immune activity.
Also read: Microplastics Accumulation In Dementia Patients More Than Others, Study Finds
The researchers also examined human samples and detected different types of microplastics found in colorectal cancer tissues and blood.
This adds to earlier research investigating the presence of plastic particles in human tumours. A 2025 study reported higher concentrations of microplastics in colorectal tumour tissue than in nearby healthy tissue.
However, detecting microplastics in cancer tissue does not establish whether the particles contributed to tumour development. More human research is needed to understand this relationship.
The findings come amid growing concern about early-onset colorectal cancer, which refers to diagnoses in people younger than 50.
According to The Washington Post, colorectal cancer rates among adults aged 20 to 49 in the US increased by approximately 3% annually between 2013 and 2022.
Researchers have been investigating several possible reasons, including dietary patterns, sedentary behaviour, environmental exposures and changes in the gut microbiome.
However, microplastics remain one of several possible environmental contributors under investigation. There is currently insufficient evidence to attribute the rise in early-onset colorectal cancer to plastic exposure.
Completely avoiding microplastics can be challenging because they are widespread in the environment. However, some precautions can help reduce exposure.
Credit: iStock
Ivonescimab, a much-anticipated lung cancer drug developed by China's Akeso in partnership with US-based Summit Therapeutics, has been rejected by the US Food and Drug Administration (FDA).
The drug, a PD-1 x VEGF bispecific antibody, was being evaluated in combination with chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer had progressed after treatment with EGFR-targeted drugs.
The FDA's decision came after a late-stage clinical trial showed that ivonescimab significantly delayed disease progression but failed to demonstrate a statistically significant improvement in overall survival (OS), a key measure of how long patients live after starting treatment.
In its Complete Response Letter (CRL), the regulator said the improvement in progression-free survival (PFS), without a statistically significant OS benefit, "did not establish a favorable benefit-risk profile to support approval".
Also read: 1 In 5 US Lung Cancer Patients Never Smoked: Report Highlights Hidden Risk Factors
The FDA's decision was based on findings from the Phase III HARMONi trial, which compared ivonescimab plus platinum-based chemotherapy with chemotherapy alone.
The combination reduced the risk of disease progression or death by 48% compared with chemotherapy alone, meeting the trial's primary PFS endpoint.
However, the primary overall survival analysis did not demonstrate a statistically significant benefit. This meant that although patients receiving ivonescimab experienced a delay in their cancer worsening, the trial did not establish that the treatment helped them live significantly longer.
Summit subsequently submitted updated analyses based on longer follow-up. The company said these showed a consistent survival benefit across Asian and Western patient groups.
However, the FDA maintained that the available evidence did not establish the survival benefit needed to support approval.
Ivonescimab is an investigational PD-1 x VEGF bispecific antibody designed to target two proteins involved in cancer growth and immune evasion.
PD-1 is an immune checkpoint protein that cancer cells can exploit to evade immune attacks. Blocking this pathway can help the immune system recognize and attack cancer cells.
VEGF, meanwhile, helps tumors develop new blood vessels that supply oxygen and nutrients, supporting their growth. Blocking VEGF can interfere with this process.
By targeting both pathways, ivonescimab combines two approaches to fighting cancer: helping the immune system attack tumors and disrupting the blood supply that supports their growth.
The drug is administered through an intravenous infusion.
Ivonescimab had attracted considerable attention because of its dual-targeting approach and potential applications beyond lung cancer.
Its developers had hoped that the drug could eventually challenge Merck's Keytruda, one of the world's best-selling cancer medicines.
Several major pharmaceutical companies, including Merck and Pfizer, are also exploring therapies that combine immune checkpoint inhibition with VEGF targeting.
However, cancer researchers have cautioned against assuming that promising early results will translate into broad clinical benefits across different cancer types.
The FDA's rejection concerns a specific lung cancer indication and does not automatically determine the outcome of ivonescimab trials in other cancers.
Despite the regulatory setback, ivonescimab's development programme continues.
Summit is evaluating the drug in several other cancers, including non-small cell lung cancer, colorectal cancer, urothelial cancer and renal cell carcinoma.
The company and Akeso have reported five positive Phase III studies across their development programmes and have said they remain committed to advancing the drug.
© $2026 Times Horizon Private Limited